First-in-Human gene therapy trial aims to halt inherited blindness
NCT ID NCT07241169
Summary
This is a very early, first-in-human study to check if a new gene therapy drug called ZVS106e is safe for people with Stargardt disease, a genetic condition that causes vision loss. It will involve 9 participants who have a specific genetic mutation. Doctors will inject the drug into the back of one eye and monitor patients closely for a year to look for side effects and any early signs that it might help preserve or improve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.